Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
LABNEW (LAB) 24-hour amplitude 40.3%: Low liquidity trading activity triggers sharp volatility

LABNEW (LAB) 24-hour amplitude 40.3%: Low liquidity trading activity triggers sharp volatility

Bitget PulseBitget Pulse2026/04/19 13:37
Show original
By:Bitget Pulse

Volatility Brief

Over the past 24 hours, LABNEW's price rebounded from a low of $0.45498 to a high of $0.63822, currently quoted at $0.63661, reflecting a price fluctuation of 40.3%. Public data platforms (such as DexScreener, Birdeye) show that this token is a low-liquidity asset, with 24-hour trading volume showing no significant anomalous surge, and limited data on net capital inflows and outflows.

Analysis of the Cause of the Movement

- No official announcements, mainstream news, or significant on-chain whale trades have been observed in the past 24 hours;

- The movement mainly stems from amplified trading effects under low liquidity conditions, similar to the whale accumulation and high trading volume-driven rebounds referenced in recent Bitget reports, but with no fresh 24-hour validation events.

Market Opinion and Outlook

Community discussions (such as on X platform) display generally short-term bullish sentiment toward LAB-related tokens, with trading signals indicating rebound potential above $0.70, but emphasizing high risk and key support zones between $0.42-$0.54. Analysts caution that low liquidity is prone to manipulation, recommend tracking transaction confirmations, and advise against chasing highs.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16